Investigation of physician countermeasures for mild progression after treatment with EGFR-TKI in lung adenocarcinoma
10.12354/j.issn.1000-8179.2025.20240687
- VernacularTitle:对EGFR敏感突变肺腺癌TKI治疗后轻微进展医生对策的调查
- Author:
Wang QIMING
1
;
Wang LU
;
Yu HONGFAN
;
Shen BO
;
Chen CHENG
;
Yan ZHAO
;
Huang CHENG
;
Wang YUMENG
;
Li KAI
;
Wang JING
;
Shi QIULING
Author Information
1. 郑州大学附属肿瘤医院(河南省肿瘤医院)内科,河南省医学科学院肿瘤研究所(郑州市 450008)
- Publication Type:Journal Article
- Keywords:
lung adenocarcinoma;
epithelial growth factor receptor tyrosine kinase inhibitor(EGFR-TKI);
stable disease(SD);
pe-metrexed;
anti-angiogenic therapy
- From:
Chinese Journal of Clinical Oncology
2025;52(3):109-114
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the views of doctors on the incidence and treatment tactics of mild progression after epithelial growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)treatment in lung adenocarcinoma and provide suggestions to optimize the counter-measure strategies.Methods:Convenience sampling was used to conduct an online questionnaire survey for doctors specializing in onco-logy and respiratory diseases.Results:584 valid questionnaires were collected,and all the doctors expressed concerns regarding mild tumor progression after EGFR-TKI treatment.The coping strategies included maintaining the original TKI treatment,adding other treatments to the original TKI,changing the regimen,and performing secondary tissue biopsy,among which,most doctors chose to add other treatments to the original TKI.Conclusions:Doctors have noticed the enlargement of target lesions in still stable disease(SD)and most frequently chose to add other treatments to the original TKI as a coping strategy.This finding can provide a reference for framing future guidelines for large sample prospective clinical studies that are needed to find the most effective synergistic treatment options.
